Chinese company tests PD-L1 agent in HBV(!?)… https://www.prnewswire.com/news-releases/ascletis-received-approval-of-clinical-trials-in-hbv-patients-for-asc22-a-subcutaneously-administered-pd-l1-antibody-300991810.html